---
layout: default
title: Vasopressin
parent: Model Prediction Only (L5)
nav_order: 875
evidence_level: L5
indication_count: 10
---

# Vasopressin
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

Using no additional skill — this is a direct, fully-specified report-generation task per the provided template; proceeding straight to drafting.

# Vasopressin: From Original Indication (Not Documented) to Congenital Prothrombin Deficiency

## One-Sentence Summary

> Vasopressin (DrugBank DB00067) is an endogenous antidiuretic hormone; this evidence pack does not contain its original approved indication or mechanism-of-action data.
> The TxGNN model's top prediction links it to **Congenital Prothrombin Deficiency**, with a **99.63% prediction score**,
> but this is supported only by **3 low-tier case reports/reviews** and **no clinical trials**, and the underlying literature actually concerns a different drug (desmopressin) treating a different disorder (factor V/VIII deficiency) — evidence for this specific pairing is weak and mechanistically inconsistent.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (no India licenses or original_indications on record in this evidence pack) |
| Predicted New Indication | Congenital Prothrombin Deficiency |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 (model prediction only, no direct supporting studies) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for vasopressin is not available in this evidence pack (flagged as a High-severity data gap requiring a DrugBank MOA lookup). Without MOA data, mechanistic plausibility for this specific drug–disease pair cannot be independently confirmed from first principles.

More importantly, the evidence collected for this candidate does not actually support the pairing. All three cited publications discuss **desmopressin (DDAVP)** — a synthetic, V2-receptor-**selective** vasopressin analogue — used for **combined factor V/VIII deficiency**, not for **prothrombin (factor II) deficiency**, and not for vasopressin itself. Congenital prothrombin deficiency is caused by mutations in the prothrombin gene affecting the coagulation cascade; there is no known pharmacological pathway by which vasopressin (a V1/V2 receptor agonist acting on vascular smooth muscle and renal collecting ducts) would correct a coagulation factor synthesis defect. This pattern — a high TxGNN similarity score with literature that references a *related but distinct* drug and a *related but distinct* disease — is consistent with a knowledge-graph embedding artifact rather than a genuine pharmacological signal.

This assessment is reinforced by the broader candidate set in this evidence pack: of the 10 TxGNN-predicted indications reviewed for vasopressin, all received a **Hold** recommendation. The highest-evidence candidate (rank 10, "cystic neoplasm," L3) was in fact built on clinical trials of **tolvaptan**, a V2-receptor **antagonist**, used to *slow* cyst growth in ADPKD — the pharmacological opposite of what a vasopressin agonist would be expected to do. No candidate in the set has evidence that is both mechanistically coherent and clinically supportive.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this indication.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [21115138](https://pubmed.ncbi.nlm.nih.gov/21115138/) | 2011 | Review | Autoimmunity Reviews | Reviews acquired hemophilia A (autoantibodies against factor VIII); does not address prothrombin deficiency or vasopressin |
| [2607619](https://pubmed.ncbi.nlm.nih.gov/2607619/) | 1989 | Case Report | Rinsho Ketsueki | DDAVP (desmopressin, a vasopressin analogue) used in a patient with combined factor V and VIII deficiency — not prothrombin deficiency |
| [1942544](https://pubmed.ncbi.nlm.nih.gov/1942544/) | 1991 | Case Report | Rinsho Ketsueki | Factor VIII replacement (not vasopressin) used to manage cesarean section in a patient with combined factor V/VIII deficiency |

None of the retrieved literature directly studies vasopressin in congenital prothrombin deficiency.

---

## India Market Information

Vasopressin is currently **not registered or marketed in India** — 0 licenses are on record in this evidence pack.

---

## Safety Considerations

**Drug Interactions** (from DDI database, 121 total interactions on record; major-severity interactions shown below):

| Interacting Drug | Severity |
|---|---|
| Dolasetron | Major |
| Cisapride | Major |
| Papaverine | Major |
| Macimorelin | Major |

Additional moderate-level interactions on record include famotidine, epinephrine, loperamide, clarithromycin, levofloxacin, ondansetron, granisetron, promethazine, cilostazol, and heparin, among others.

Key warnings and contraindications are not available in this evidence pack; refer to the official product label once available.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction is supported only by L5 (model-only) evidence, with the underlying literature referencing a different drug (desmopressin) and a different disease (factor V/VIII deficiency) than the one predicted. No clinical trials exist for this specific pairing, and no plausible mechanistic pathway connects vasopressin to prothrombin synthesis. All 10 TxGNN-predicted indications reviewed for this drug carry the same Hold recommendation, including one case with a mechanistically contradictory drug-direction issue (agonist predicted for a disease treated by antagonists).

**To proceed, the following is needed:**
- TFDA/regulatory label data (blocking gap): warnings, contraindications, and approved indications
- DrugBank mechanism-of-action data for vasopressin
- Direct clinical or mechanistic evidence specifically linking vasopressin (not its analogues) to congenital prothrombin deficiency
- Given the uniformly weak evidence across all 10 candidates, consider deprioritizing this drug-target pair pending new data rather than advancing further evaluation stages
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

